Diagnostics & imaging AI · Augmented reality surgical navigation
MediView
MediView is a Cleveland, Ohio company whose FDA-cleared XR90 system uses an augmented reality headset to show 3D CT anatomy fused with live ultrasound inside the patient, helping interventional radiologists guide biopsies, ablations, and other needle procedures.
Strong fit
- Interventional radiology and oncology teams doing ultrasound-guided biopsies and ablations of deep or hard-to-see targets
- Hospitals that want 3D guidance without adding radiation
- Academic centers that also use augmented reality for training
Weak fit
- Departments that do few image-guided needle procedures
- Buyers who need a long published outcomes record
- Teams that are not ready to add headsets and image fusion steps to their room setup
Bottom line
MediView gives interventional radiologists a head-up 3D view of a patient's CT anatomy, aligned with live ultrasound, while they place a needle. It suits teams doing difficult biopsies and ablations who want more confidence without more radiation. Clinical evidence and installations are still early.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
MediView's users are interventional radiologists and other proceduralists who guide needles with ultrasound or CT. In a typical case, the XR90 system takes the patient's CT scan, builds a 3D model of the organs, vessels, and target, and shows it inside the patient through an augmented reality headset, aligned with live ultrasound. The company calls this giving clinicians "X-ray vision." Its first focus is liver and kidney tumors, where a clearer view can make ablation a more practical option.
Alternatives are other augmented reality navigation systems, such as Augmedics and Medivis, and conventional navigation systems that track needles on 2D screens. MediView sells a quoted capital system, which puts it in the price range of other surgical navigation equipment.
MediView was founded on technology from Cleveland Clinic's Lerner Research Institute. In October 2025 it closed a $24 million Series A led by GE HealthCare, with Cleveland Clinic, Mayo Clinic, Edge Ventures, Emplify Health's investment arm, and JobsOhio Growth Capital Fund. Its revenue is an estimated $3 million a year.
Real-world use is still early. In August 2026 Cleveland Clinic Weston Hospital became the first Florida hospital to use XR90, for a liver biopsy of a lesion about 10 cm deep. The company also launched a multicenter study of XR90 for soft tissue biopsy. Teams should plan for setup and training time, since headsets and image fusion add steps until a team is practiced.
What clinicians and buyers say
What people like
"Seeing the CT anatomy in 3D inside the patient while I scan with ultrasound helps with deep targets I can barely see on the screen."
"I can keep my eyes on the patient during the procedure, which helps my posture."
What people don't like
"Headset setup and image registration add time until the room is practiced."
"There is not much published outcomes data yet, so we are relying on early cases."
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums, and product documentation.
Based on: MediView homepage, October 2025 Series A release, and Cleveland Clinic Weston first-use release.
Pricing
| Item | Detail |
|---|---|
| Model | Capital system and software for the XR90 platform, quoted per site. List prices are not published. |
| What drives cost | Number of systems, headsets, imaging integrations, training, and service terms. |
Leadership
Recent news
- August 2026: Cleveland Clinic Weston Hospital performed the first XR90 procedure in Florida, a liver mass biopsy guided by fused CT and ultrasound.
- December 2025: MediView received its first CE mark, allowing it to introduce its augmented reality products in Europe.
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.